Compare Msci Inc (MSCI) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Msci Inc vs GeneDx Holdings Corp — how do they compare? Msci Inc trades at $565.12 (market cap $40.38B), while GeneDx Holdings Corp trades at $67.33 (market cap $2.02B). The key difference: Msci Inc is far larger — about 20× GeneDx Holdings Corp's market cap, and Msci Inc pays a 1.48% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold Msci Inc for 82 Days and GeneDx Holdings Corp for 19 Days on average.
| MSCI | WGS | |
|---|---|---|
Market Cap | $40.38B | $2.02B |
Volume | 414,140 | 734,640 |
Sector | Financials | Health |
52-Week High | $643.83 | $167.51 |
52-Week Low | $511.84 | $34.51 |
Typical Hold Time | 82 Days | 19 Days |
Enterprise Value | $46.54B | $2.05B |
Dividend Yield | 1.48% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MSCI trades at $561.67, up 1.13% on the day, with a bullish technical signal and strong fundamentals. The stock shows consistent revenue growth, reaching $3.13B in 2025, with a high net income margin of 40.73%. Recent earnings have mostly beaten expectations, and the company maintains robust cash flow from operations. Analyst consensus is strongly positive, with a $701.71 price target, supported by 74% buy ratings. Key developments include the completed acquisition of First Street, enhancing its climate risk analytics offerings.
The outlook for MSCI is favorable, driven by recurring revenue streams, high client retention, and growth in passive investing and private markets. Risks include high valuation multiples, significant long-term debt of $4.51B, and sensitivity to financial market cycles. The stock presents a long-term growth opportunity, but investors should monitor execution on earnings and debt management.
GeneDx (WGS) trades at $67.73, down 1.17% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth to $454M in 2026 but faces profitability challenges with a -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target.
The stock presents a growth story with expanding genomic testing volumes but carries significant execution risk given negative profitability metrics. Upside potential exists if management can translate revenue growth into sustainable profits, though current cash flow trends and high valuation multiples warrant caution for risk-averse investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Msci Inc
MSCI describes its mission as enabling investors to build better portfolios for a better world. MSCI's largest and most profitable segment is its index segment, where it provides benchmarking to asset managers and asset owners. In addition, it boasts over $1 trillion in ETF assets linked to MSCI indexes. The MSCI analytics segment provides portfolio management and risk management analytics software to asset managers and asset owners. MSCI's all other segment was broken out into ESG and climate and private assets segments in 2021. In ESG and climate, MSCI provides ESG data to the investment industry. In the private assets side, MSCI provides real restate reporting, market data, benchmarking, and analytics to investors and real estate managers.
Read more on MSCI →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
